CRISPR-based gene editing technology is revolutionizing the biopharma industry, enabling advances in disease modeling that were impossible just a few years ago. CRISPR-Cas9 enables precise, directed creation of Knock-Outs and Knock-Ins (including single base changes) in all types of cells. REPROCELL provides CRISPR-Cas9 gene editing in collaboration with GenAhead Bio.
Our technology uses the proprietary SNIPER method to screen for positive clones. This streamlines the most time-consuming part of the CRISPR-based gene editing: Screening colonies for positives.
Traditional Knock In generation uses a screening gene, such as PurR or GFP to aid in identifying positive colonies (Left panel, below). For single base change generation, use of screening genes is not possible, since only the desired base change is allowed (Center panel, below). This means that a method like PCR of colony sequencing is required to identify positive clones, resulting in a significant investment in time and resources. Adding a SNIPER screen to single base change modification screening results in 100-fold or greater increase in positive clones, which greatly speeds this resource-intensive step.
Figure: Scheme for generation of Knock Ins (Left Panel) and Single Base Changes (Center Panel) using CRISPR-Cas9. Results of colony screening using traditional and SNIPER-based screening (Right Panel).
SNIPER (Specification of Newly Integrated Position and Exclusion of Random-integration) is proprietary technology of GenAhead Bio. SNIPER enables easy detection of successfully knocked-in clones to speed identification of positive clones.
CRISPR-Cas9 Gene Editing using SNIPER can be combined with our Custom Stem Cell Services to create unique, custom disease models tailored to your needs. Contact us to find out more.
For more technical information, please see our webinar: CRISPR/Cas9 using SNIPER Technology - Managing Challenging Cases